Back to News
Market Impact: 0.35
Lilly's Omvoh Meets Primary Endpoint In Phase 3 Pediatric Ulcerative Colitis Study
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Eli Lilly reported positive Phase 3 SHINE-2 results for Omvoh in pediatric ulcerative colitis: one in two patients who responded to initial treatment remained in clinical remission after one year. The article excerpt provides no further trial details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
LLY0.75
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Here are Monday's biggest analyst calls: SpaceX, Nvidia, Apple, CoreWeave, Amazon, Meta, Eli Lilly & more
- Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy Points
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Walmart’s Flipkart is quietly building a food delivery challenger in India